PT - JOURNAL ARTICLE AU - Sandra Sanchez-Roige AU - Mariela V Jennings AU - Hayley H A Thorpe AU - Jazlene E Mallari AU - Lieke van der Werf AU - Sevim B Bianchi AU - Yuye Huang AU - Calvin Lee AU - Travis T Mallard AU - Samuel A Barnes AU - Jin Yi Wu AU - Amanda M Barkley-Levenson AU - Ely C Boussaty AU - Cedric Snethlage AU - Zeljana Babic AU - Boyer D Winters AU - Katherine E Watters AU - Thomas Biederer AU - 23andMe Research Team AU - James Mackillop AU - David N Stephens AU - Sarah L Elson AU - Pierre Fontanillas AU - Jibran Y Khokhar AU - Jared W Young AU - Abraham A Palmer TI - <em>CADM2</em> is implicated in impulsive personality traits by genome- and phenome-wide association studies in humans, with further support from studies of <em>Cadm2</em> mutant mice AID - 10.1101/2022.01.29.22270095 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.29.22270095 4099 - http://medrxiv.org/content/early/2022/02/03/2022.01.29.22270095.short 4100 - http://medrxiv.org/content/early/2022/02/03/2022.01.29.22270095.full AB - Background Impulsivity is a multidimensional heritable phenotype that broadly refers to the tendency to act prematurely and is associated with multiple forms of psychopathology.Methods We performed genome-wide association studies (GWAS) of eight impulsive personality traits from the Barratt Impulsiveness Scale and the short UPPS-P Impulsive Personality Scale (N=123,509-133,517 23andMe research participants of European ancestry), and a measure of Drug Experimentation (N=130,684). Because these GWAS implicated the gene CADM2, we next performed a phenome-wide study (PheWAS) in a multi-ancestral 23andMe cohort (N=3,229,317, European; N=579,623, Latinx; N=199,663, African American). Finally, we produced Cadm2 knock-out mice and tested them using a battery of behavioral impulsivity tasks.Results In humans, impulsive personality traits showed modest chip-heritability (∼6-10%), and moderate genetic correlations (rg=.20-.50) with other personality traits, and various psychiatric and medical traits. We replicated associations from earlier GWAS of these traits and found novel associations including DRD2, CRHR1, FOXP2, TCF4, PTPRF. PheWAS for CADM2 identified associations with 378 traits in European participants, and 47 traits in Latinx participants, replicating associations with risky behaviors, and revealing novel associations including allergies, anxiety, irritable bowel syndrome, and migraine. Cadm2 knock-out mice showed reduced impulsivity in the 5-choice serial reaction time task, while heterozygote mice showed lower risky behavior in the mouse Iowa gambling task.Conclusions Our results further establish the role of CADM2 in impulsivity and numerous other psychiatric and somatic traits across ancestries. Additionally, we demonstrate that deletion of Cadm2 in mice influences behavior in assays designed to measure impulsive and risky behavior.Competing Interest StatementPF and SLE are employees of 23andMe, Inc., and hold stock or stock options in 23andMe. JY reports having received grant support funding from Sunovion, Heptares, and Gilgamesh, as well as honoraria from Marvel Biotech, none of which were involved in the current project. The other authors report no conflict of interest.Funding StatementMVJ, SBB, SSR and AAP were supported by funds from the California Tobacco-Related Disease Research Program (TRDRP; Grant Number 28IR-0070 and T29KT0526). SBB was also supported by P50DA037844, SSR was also supported by NIDA DP1DA054394. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. AMBL was supported by NIH-NIAAA grant K99AA027835. TB acknowledges support by NIH/NIDA R01 DA018928. JM is supported by the Peter Boris Chair in Addictions Research. HHAT is funded through a Natural Science and Engineering Research Council PGS-D scholarship, and studies in Cohort 2 were supported by the Canadian Institutes of Health Research Project Grant (PJT-173442 to JYK).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants were drawn from the research participant base of 23andMe, Inc., a direct-to-consumer genetics company, and were not compensated for their participation. Participants provided informed consent and participated in the research online, under a protocol approved by the external AAHRPP-accredited IRB, Ethical &amp; Independent Review Services (www.eandireview.com). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe will provide summary statistics for the top 10,000 SNPs upon publication (Tables S22-30). Full GWAS summary statistics will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. Please visit https://research.23andme.com/collaborate/#dataset-access/ for more information and to apply to access the data.